-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

902. Health Services Research—Malignant Conditions (Lymphoid Disease): Poster II

Program: Oral and Poster Abstracts
Type: Poster
Hematology Disease Topics & Pathways:
Adult, ALL, antibodies, Biological, Leukemia, multiple myeloma, survivorship, CLL, Diseases, Lymphoma (any), Non-Biological, CAR-Ts, Hodgkin Lymphoma, Therapies, Adverse Events, chemotherapy, CNS Lymphoma, Non-Hodgkin Lymphoma, B-Cell Lymphoma, DLBCL, T-Cell Lymphoma, Technology and Procedures, immunotherapy, Plasma Cell Disorders, Lymphoid Malignancies, Study Population, Clinically relevant, Myeloid Malignancies, Quality Improvement , transplantation, TKI, stem cells
Sunday, December 6, 2020: 7:00 AM-3:30 PM

Anthony Mato, MD1*, Boxiong Tang, MD, PhD2, Soraya Azmi, MBBS, MPH2*, Keri Yang, PhD, MPH, MS2*, Jennifer C Stern, PhD3*, Eric Hedrick, MD3, Jane Huang, MD4* and Jeff P Sharman, MD5

1Memorial Sloan Kettering Cancer Center, New York, NY
2BeiGene, Ltd., Emeryville, CA
3BeiGene, Ltd., Cambridge, MA
4BeiGene USA, Inc., San Mateo, CA
5Willamette Valley Cancer Institute, Eugene, OR

Tycel J. Phillips, MD1*, Kristina Yu-Isenberg, PhD, MPH, RPh2*, Nicholas Liu, PharmD2*, Andy Surinach, MPH3*, Carlos Flores, MPH3*, Julie Lisano, PharmD2*, Michelle A. Fanale, MD2 and John M. Burke, MD4

1Department of Internal Medicine, Division of Hematology/Oncology, University of Michigan Medical School, Ann Arbor, MI
2Seattle Genetics, Bothell, WA
3Genesis Research, Hoboken, NJ
4US Oncology Hematology Research Program, Rocky Mountain Cancer Centers, Aurora, CO

Iman Mohammadi, PhD1*, Anna G Purdum, Pharmd MS2*, Anny C Wong, PhD3*, Amy Schroeder, BPharm1*, Karl M Kilgore, PhD4* and Gunjan L. Shah, MD MS5

1Avalere Health, An Inovalon Company, Washington, DC
2Kite Pharma, A Gilead Company, Santa Monica, CA
3Health Economics and Advanced Analytics, Avalere Health, An Inovalon Company, Washington, DC
4Health Economics and Advanced Analytics, Avalere Health, An Inovalon Company, Towson, MD
5Department of Medicine, Adult Bone Marrow Transplant Service, Memorial Sloan Kettering Cancer Center, New York, NY

Kristen Rosenthal, PhD1*, Jeremy S Abramson, MD, MMSc2, Farrukh T Awan, MD3, John P. Leonard, MD4, Julie M. Vose, MD, MBA5, Timothy A Quill, PhD6* and Christopher Flowers, MD, MS7

1CLINICAL CARE OPTIONS LLC, Reston, VA
2Massachusetts General Hospital Cancer Center, Boston, MA
3Division of Hematologic Malignancies and Stem Cell Transplantation, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX
4Weill Cornell Medical College, New York, NY
5Division of Oncology and Hematology, University of Nebraska Medical Center- Fred & Pamela Buffett Cancer Center, Omaha, NE
6Clinical Care Options, LLC, Reston, VA
7Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX

Fei Yang, MBBS, MMSc, PhD1*, Anup Abraham, MPH2*, Ju Zhang, MSPH, PhD3*, Yan Xiao, MD, PhD3*, Richard D. Hammer, MD4*, Donald C. Doll, MD4,5 and Matthew S. Prime, BSc, MBBS, MRCS, PhD1*

1Roche Diagnostics Information Solutions, Basel, Switzerland
2Genesis Research, Hoboken, NJ
3Roche Diagnostics Information Solutions, Belmont, CA
4University of Missouri, Columbia, MO
5Ellis Fischel Cancer Center, Columbia, MO

Anita J Kumar, MD, MS1,2, Jason Nelson, MPH1*, Angie Mae Rodday, PhD1, Andrew M. Evens, DO, MMSc3, Jonathan W. Friedberg, MD, MSSc4, Tanya M. Wildes, MD, MSc5 and Susan K Parsons, MD, MRP1,6,7

1Institute for Clinical Research & Health Policy Studies, Tufts Medical Center, Boston, MA
2Division of Hematology/Oncology, Tufts Medical Center, Winchester, MA
3Rutgers Cancer Institute of New Jersey, New Brunswick, NJ
4Division of Hematology/Oncology, University of Rochester, Rochester, NY
5Washington University, Saint Louis, MO
6Division of Hematology/Oncology, Tufts Medical Center, Boston, MA
7Department of Medicine and Pediatrics, Tufts University School of Medicine, Boston, MA

Natalie M Dren, BSc, MPH1* and Lorna E Warwick2*

1Research, Lymphoma Coalition, Mississauga, ON, Canada
2Management, Lymphoma Coalition, Mississauga, ON, Canada

Emelly Rusli1*, Lihong Diao, MD MS2*, Cynthia Liu3,4*, Mona A Kelkar, MBA3,5*, Lisa Ensign, PhD MS2*, Mark Watson, MD PhD6* and Aaron Galaznik, MD MBA1

1Acorn AI by Medidata, a Dassault Systèmes Company, Boston, MA
2Acorn AI by Medidata, a Dassault Systèmes Company, New York, NY
3Acorn AI Institute, Medidata, a Dassault Systèmes Company, New York, NY
4Columbia Mailman School of Public Health, New York, NY
5Harvard T.H. Chan School of Public Health, Boston, MA
6Guardian Research Network, Inc., Spartanburg, SC

Neda Alrawashdh, PharmD1*, Ali McBride, PharmD, MS2,3, Marion Slack, Ph.D4* and Ivo Abraham, PhD, RN5

1Center for Health Outcomes and PharmacoEconomic Research, University of Arizona, TUCSON, AZ
2University of Arizona Cancer Center, Tucson, AZ
3Division of Hematology/Oncology, Department of Pharmacy, The University of Arizona Cancer Center, Tucson, AZ
4University of Arizona, TUCSON, AZ
5Center for Health Outcomes and PharmacoEconomic Research, University of Arizona - College of Pharmacy, Tucson, AZ

Amit Sanyal1, Susan K Woelich, PharmD2*, Matthew Mattila, PharmD3*, Stephanie McCleary, PharmD4*, James Thomas, PharmD5* and Daniel Wellner, PharmD, BCPS6*

1SSM Health Cancer Care, Verona, WI
2SLU, St. Louis
3SSM Health, Fond Du Lac, WI
4SSM Health, St. Louis
5ssm health, St. Louis
6SSM Health Cancer Care, madison

Akshat M Patel, BA1*, Omer M Ali, MD1, Radhika Kainthla, MD2*, Syed M Rizvi, MD1*, Farrukh T Awan, MD1, Neil B Desai, MD, MHS3*, Robert Timmerman, MD3*, Kiran A Kumar, MD, MBA3* and Praveen Ramakrishnan Geethakumari, MD, MS1

1Division of Hematologic Malignancies and Stem Cell Transplantation, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX
2Parkland Health and Hospital System, Dallas, TX
3Department of Radiation Oncology, University of Texas Southwestern Medical Center, Dallas, TX

Xiangyun Ye1*, Catherine Tucker, MD2*, Christopher Gardner1*, Austin Redilla1*, Guldeep Uppal, MD3* and Adam F. Binder, MD4

1Sidney Kimmel Medical College, Philadelphia, PA
2Department of Pathology, Philadelphia, PA
3Pathology, Thomas Jefferson University, Philadelphia, PA
4Division of Hematologic Malignancies and Hematopoietic Stem Cell Transplantation, Department of Medical Oncology, Thomas Jefferson University, Philadelphia, PA

Talha Munir, MBBS1*, Priyanka Gaitonde2* and Catherine Waweru, PhD2*

1St James University Hospital, Leeds, United Kingdom
2AstraZeneca, Gaithersburg, MD

Ali McBride, PharmD, MS1 and Daniel O. Persky, MD2

1Division of Hematology/Oncology, Department of Pharmacy, The University of Arizona Cancer Center, Tucson, AZ
2Division of Hematology/Oncology, University of Arizona, Tucson, AZ

Lane Miller, MD, MSc1*, Mylynda Livingston, CNP2*, Stuart S. Winter, MD3, Dave Watson, PhD4* and Yoav H. Messinger, MD5

1Cancer and Blood Disorders, Children's Minnesota, Minneapolis, MN
2Cancer & Blood Disorders, Children's Minnesota, Minneapolis, MN
3Children's Minnesota Research Institute, Children's Minnesota Research Institute and Cancer and Blood Disorders Program, Minneapolis, MN
4Research Institute, Children's Minnesota, Minneapolis, MN
5Children's Hospitals and Clinics, Minneapolis, MN

Fernando Ramos1*, Marta Castellanos, MD2*, Natalia De las Heras, MD2*, Fernando Escalante, MD2*, Silvia Fernandez-Ferrero, MD PhD2*, Maria Jesus Vidal, MD2* and Maria Lavinia Villalobos, MD2*

1Department of Hematology, Hospital Universitario De LeóN and Instituto De Biomedicina (IBIOMED), Un, Leon, Spain
2Department of Hematology, Hospital Universitario de Leon, Leon, Spain

M. Lia Palomba, MD1, Monika P. Jun, MPH2*, Jacob Garcia, MD3*, James Lymp, PhD3*, November McGarvey4*, Matthew Gitlin4*, Corey Pelletier5* and Andy Nguyen4*

1Memorial Sloan Kettering Cancer Center, New York, NY
2Bristol-Myers Squibb Company, Princeton, NJ
3Juno Therapeutics, a Bristol-Myers Squibb Company, Seattle, WA
4BluePath Solutions, Los Angeles, CA
5Bristol Myers Squibb, Princeton, NJ

Michael E Auster, DO1*, Snegha Ananth, MBBS2,3, Lakene Raissa Djoufack Djoumessi, MD2*, Qianqian Liu, PhD4*, Joel E Michalek, PhD5* and Adolfo Enrique Diaz Duque, MD, MSc6

1University of Texas Health Science Center at San Antonio, San Antonio, TX
2University of Texas Health Science Center San Antonio, San Antonio, TX
3Hematology-Oncology, Mays Cancer Center UT Health San Antonio MD Anderson, San Antonio, TX
4Department of Epidemiology and Biostatistics, University of Texas Health at San Antonio, San Antonio, TX
5The University of Texas Health Science Center At San Antonio, San Antonio, TX
6Hematology-Oncology Division, Mays Cancer Center UT Health San Antonio MD Anderson, San Antonio, TX

Andrew J. Cowan, M.D.1, Shasank R Chennupati, PharmD, MPH2*, Yuan Xu, PhD3*, Ang Li, MD, MS4, David A. Garcia, MD5, Edward Libby, MD6, Catherine Fedorenko, MMSci7*, Scott D Ramsey, MD, PhD7*, Veena Shankaran, MD7,8* and Winson Y Cheung, MD MPH9*

1Division of Medical Oncology, University of Washington, Seattle, WA
2Hutchinson Institute for Cancer Outcomes Research, Fred Hutchinson Cancer Research Center, Seattle, WA
3Alberta Health Services, Calgary, AB, Canada
4Section of Hematology-Oncology, Baylor College of Medicine, Houston, TX
5Department of Medicine, Division of Hematology, University of Washington, Seattle, WA
6Division of Medical Oncology, Department of Medicine, University of Washington, Seattle, WA
7Fred Hutchinson Cancer Research Center, Seattle, WA
8Medicine, University of Washington, Seattle, WA
9Department of Oncology, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada

F. B. B. Hagemeister, MD1, Anne Jacobson, MS2*, Jeffrey D Carter, PhD2* and Tamar Sapir, PhD2*

1Department of Lymphoma/Myeloma, University of Texas MD Anderson Cancer Center, Houston, TX
2PRIME Education, LLC, Ft Lauderdale, FL

*signifies non-member of ASH